Patent applications published 3 November 2010

Published: 22-Nov-2010

Selected patent applications from the weekly European Patents Bulletin


  • Tricyclic compounds as modulators of TNF-synthesis and as PDE4 inhibitors
    High Point Pharmaceuticals 2244574*

  • Angiotensin II receptor antagonists
    Merck Sharp & Dohme 2244575*

  • 3,5-substituted-1,3-oxazolidin-2-one derivatives
    Merck Sharp & Dohme 2244576*

  • Quinolizidinone M1 receptor positive allosteric modulators
    Merck Sharp & Dohme 2244577*

  • Inhalation drug products, systems and uses
    Schering 2244692*

  • Agent for intra-articular injection
    Kief, Horst 2244693*

  • Therapeutic compsns comprising an amine-containing lipid and a protein
    Shire Human Genetic Therapies 2244694*

  • Compsns for inducing immune responses
    Novartis 2244695*

  • Carrier pellets, method for the production thereof and use thereof
    IPC Process-Center; ADD Technologies 2244696*

  • Therapeutic compsns
    Shire Human Genetic Therapies 2244697*

  • Biodegradable therapeutic nanoparticles containing an antimicrobial agent
    The University of North Caroline at Charlotte Office of Technology Transfer 2244698*

  • Edible film-strips for immediate release of active ingredients
    McNiel-PPC 2244699*

  • Stromal interacting molecule knockout mouse and uses thereof
    Immune Disease Institute 2244700*

  • Corroles for Neuroprotection and Neurorescue
    Tecnion Research and Development Foundation 2244701*

  • Treatment of neural diseases or conditions
    The Royal Institution for the Advancement of Learning/McGill University 2244702*

  • Pharmaceuticals and the production and use thereof in the treatment of painful neuropathies
    PAZ Arzneimittel-Entwicklungsgesellschaft 2244703*

  • Treatment of aspirin resistance with betaine and/or betaine enriched molasses
    Messadek, Jallal 2244704*

  • Novel crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid
    AstraZeneca 2244705*

  • Glucokinase activators
    Merck Patent 2244706*

  • Tetrahydrocyclopena/c acridine derivatives as kinase inhibitors and biological applications thereof
    Centre National de la Recherche Scientifique 2244707*

  • New 2,3,4,5-tetrahydro-1H-pyrido[4,3-B]indole compounds and methods of use thereof
    Medication Technologies 2244708*

  • Topical formulations for the treatment of psoriasis Synta Pharmaceuticals 2244709*

  • A method for administering a PDE3 inhibitor via titration for the treatment of peripheral arterial disease
    Indigo Pharmaceuticals 2244710*

  • Certain chemical entities, compsns and methods
    Cytokinetics 2244711*

  • In vivo studies of crystalline forms of meloxicam
    Thar Pharmaceuticals 2244712*

  • Use of a gamma secretase inhibitor for treating cancer
    F Hoffmann-La Roche 2244713*

  • Use of picoplatin and bevacizumab to treat colorectal cancer
    Poniard Pharmaceuticals 2244714*

  • Peptides having a binding affinity to an antibody which recognises an epitope on an 1 loop 2 or 2 loop 1 of an adrenoreceptor
    Mdc Max-Delbruck-Centrum Für Moleckulare Medizin Berlin 2244718*

  • Wound healing peptides and methods of use thereof
    Tufts University 2244719*

  • Polypeptide vaccine and vaccination strategy against mycobacterium
    The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services 2244720*

  • Sulphone substituted 2,3-dihydroimidazo-[1,2-C]-quinazoline derivatives useful for treating hyperproliferative disorders and diseases with angiogenesis
    Bayer Schering Pharma 2244721*

  • Treatment of microbial infections
    The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin 2244722*

  • Compsns and methods for treating diseases associated with angiogenesis and inflammation
    Chang, Chiwen 2244723*

  • Use of peptides to promote wound healing
    Vereniging voor Christelijk Hoger Onderwijs 2244724*

  • Novel peptides and protein and uses thereof
    Agency for Science, Technology and Research, Singapore 2244725*

  • Use of Factor VIIa for Factor VIIa equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following an intracerebral haemorrhage (ICH) in a selected subpopulation of ICH patients
    Novo Nordisk 2244726*

  • A method for restoring BMP-receptor signalling in a cell
    Freie Universität Berlin 2244727*

  • Use of serine protease inhibitors in the treatment of skin diseases
    Dermadis; Institut National de la Sante et de la Recherche Medicale 2244728*

You may also like